Skip to content
Triangle logo TriangleGet started
← Study library

NCT01000753 · CITED IN SOURCE DOCUMENTS

Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
Not reported
Status at capture
COMPLETED
Registry last update
2023-10-03

This research study is collecting and storing tissue samples from patients with rare or cutaneous non-Hodgkin lymphoma. Collecting and storing samples of tissue from patients with cancer to test in the laboratory may help the study of cancer in the future.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part
eligibility Criteria
Inclusion Criteria: * Diagnosis of NHL * Any histology, except for Burkitt or Burkitt-like, diffuse large B-cell, anaplastic large cell, or lymphoblastic lymphoma * Primary CNS, primary cutaneous NHL, or lymphoproliferative diseases of any histology allowed * Pathological specimen from site not treated within the past 6 months * Must have specimens available * At least 6 months since prior chemotherapy irradiation to study lesion * At least 2 weeks since prior steroids
healthy Volunteers
false
maximum Age
21 Years
sampling Method
NON_PROBABILITY_SAMPLE
sex
ALL
std Ages
  1. CHILD
  2. ADULT
study Population
PATIENTS WITH RARE OR CUTANEOUS NHL
Treatment arms and interventions
arm Groups
  1. description
    See Detailed Description
    intervention Names
    1. Other: Cytology Specimen Collection Procedure
    label
    Observational (specimen collection)
interventions
  1. arm Group Labels
    1. Observational (specimen collection)
    description
    Correlative studies
    name
    Cytology Specimen Collection Procedure
    other Names
    1. Cytologic Sampling
    type
    OTHER
Study design
observational Model
CASE_ONLY
time Perspective
PROSPECTIVE
Enrollment
count
174
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. measure
    Clinical features, treatment, and outcomes
    time Frame
    Up to 5 years
  2. measure
    Pathologic and biologic features of these diseases, including molecular diagnostics and flow cytometry
    time Frame
    Up to 5 years
  3. measure
    Establishment of a bank of these pathologically reviewed diseases and make specimens of blood and tissue available to qualified researchers
    time Frame
    Up to 5 years
  4. measure
    Sub-groups of these diseases that could be targeted for future biologic, pathologic, or therapeutic studies
    time Frame
    Up to 5 years
Full study description
brief Summary
This research study is collecting and storing tissue samples from patients with rare or cutaneous non-Hodgkin lymphoma. Collecting and storing samples of tissue from patients with cancer to test in the laboratory may help the study of cancer in the future.
detailed Description
OBJECTIVES: I. To determine the clinical features, treatment, and outcome of patients with rare or cutaneous pediatric non-Hodgkin lymphoma (NHL). II. To determine the pathologic and biologic features of these diseases, including molecular diagnostics and flow cytometry. III. To establish a bank of these pathologically reviewed diseases and make specimens of blood and tissue available to qualified researchers. IV. To determine sub-groups of these diseases that could be targeted for future biologic, pathologic, or therapeutic studies. OUTLINE: On study data will include presenting symptoms and signs, physical description of the tumor if it is on the skin, results of metastatic evaluation, stage (if available), blood count, markers, and the results of viral serologies. Any existing underlying conditions that could predispose to lymphoma will also be noted. Demographic and outcomes data will be stored and maintained by the COG Research Data Center. Demographic data will be linked to the specimen data in the BPC database. The approach of this study is prospective data collection, including central pathologic review, relevant biologic studies, submission of material to the Biopathology Center (BPC) and collection of diagnostic and outcome data. Participants will be registered with a standard COG registration form for documentation of age, gender, race, date of diagnosis, initial presentation, initial work-up, and stage according to the standard staging for the specific disease, initial diagnostic procedure, and institutional diagnosis. Tissue will be sent according to guidelines in Section 4.0. Follow-up data, including relapse or progression and vital status will be reported annually for 5 years. Patients will be followed annually for 5 years and data will be collected including vital status, evidence/absence of disease, type of treatment received, progression/relapse and whether the patient continues on study.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-c3d16aefd1e540cf2254
      requested nct id
      NCT01000753
      primary nct id
      NCT01000753
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      f1f1a2b5d12aecd8245482e171eae02ca47aedde6097c4c21b97855f62bb55e0
      payload sha256
      c91a5d803b7d722961ec7092f1230e4cc43f28087c3b6445cf14e3c4e66140bd
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-c3d16aefd1e540cf2254
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT01000753
      occurrences
      1. context exact
        rparts.[<a href="#cit/section_10.1">1</a>] </p><p id="_352" tabindex="-1">The Children's Oncology Group (COG) opened a registry study (<a href="/clinicaltrials/NCT01000753">COG-ANHL04B1</a>) to learn more about the clinical and pathological features of these rare types of pediatric non-Hodgkin lymphoma (NHL). This study banks tis
        end
        444359
        exact text
        NCT01000753
        start
        444348
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/fd36e5abb88f40b91c.html
      source file sha256
      f1f1a2b5d12aecd8245482e171eae02ca47aedde6097c4c21b97855f62bb55e0
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:22:02.430571+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      82ec317f50f4df507988e345c98b7f250d282967704c0ba2eddd7b442373575f
      source title
      Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: April 17, 2025
        datetime
        2025-04-17T12:00:00Z
        display
        April 17, 2025

    Preserved source evidence · Not medical advice